AngelEye Health Acquires EDNA Platform: Harnessing Sensors to Identify Risk in Infants with the Acquisition of the EDNA Portfolio read more 07/23/24
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock read more 08/15/23
AngelEye Health Launches Empower, a Patient-Focused Communication and Education Care Pathway to Bridge the Gap Between NICU and Home read more 06/20/23
Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients read more 10/20/22
MINDERA™ ANNOUNCES PUBLICATION OF AN ECONOMIC EVALUATION OF PRECISION MEDICINE TESTING FOR THE TREATMENT OF PSORIASIS read more 07/19/21
